Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine

German biotech company Morphosys' tafasitamab, the group's most advanced drug which is currently being tested, has sales potential of significantly more than $1 billion a year, its finance chief said in remarks to a magazine.